LA-CB1
LA-CB1 is an Abemaciclib derivative that targets CDK4/6 and promotes its degradation via the ubiquitin-proteasome pathway, thereby disrupting the CDK4/6-Cyclin D1-Rb-E2F axis and inducing G0/G1 cell cycle arrest and apoptosis. LA-CB1 exhibits antiproliferative activity against MDA-MB-231 cells, with an IC50 of 0.27 µM, and effectively inhibits epithelial-mesenchymal transition (EMT), cell migration, invasion, and angiogenesis. In highly aggressive models such as triple-negative breast cancer (TNBC), LA-CB1 significantly suppresses tumor growth in a dose-dependent manner. LA-CB1 holds potential for research in the field of breast cancer[1].
Product Specifications
CAS Number
3032908-44-1
UNSPSC
12352005
Target
Apoptosis; CDK
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Field of Research
Cancer
Concentration
10mM
Purity
98.20
Solubility
DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CC1=NC2=C(C=C(C=C2N1C(C)C)C3=CC=NC(NC4=CC(Cl)=C(C=C4)OCC5=C(C=CC=N5)C#N)=N3)F
Molecular Formula
C28H23ClFN7O
Molecular Weight
527.98
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK4; CDK6
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
RPL23AP77 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)
